Literature DB >> 11384672

Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro.

M J Barten1, J F Gummert, T van Gelder, R Shorthouse, R E Morris.   

Abstract

We have optimized assays to measure mitogen-stimulated rat lymphocyte activation in whole blood and have used these assays to quantitate the potencies of immunosuppressive drugs with different mechanisms of action. To define the optimal conditions for measuring T cell functions in whole blood, the effects of different concentrations of mitogens that activate T cells through calcium-dependent and -independent pathways were measured over time. Proliferation was measured by tritium-labeled thymidine ([3H]-TdR) incorporation and by flow cytometric analysis of proliferating cell nuclear antigen (PCNA)/DNA content. Furthermore, we detected the increases in percent expression of cell-surface activation antigens (CD25, CD134, CD71, CD11a and CD54). Concanavalin A (Con A) stimulated maximum lymphocyte proliferation and expression of T cell surface activations by 72-96 h, which was 48 h later than stimulation by phorbol 12-myristate 13-acetate (PMA) plus anti-CD28 monoclonal antibody (mAb) or PMA plus ionomycin (IONO). Addition of sirolimus, tacrolimus, cyclosporine or the active metabolite of leflunomide, A77 1726, to mitogen-stimulated whole blood produced drug concentration-dependent inhibitions of lymphocyte proliferation and expression of cell surface activation antigen expression. From these data, we determined drug potencies (inhibitory concentration of 50%, IC(50)) and drug concentrations causing maximum inhibition of T cell functions (I(max)). We developed simple and reproducible assays to measure different lymphocyte functions in whole blood cultures. These assays were used to investigate the mechanisms of different immunosuppressive drugs. These methods can be exploited to measure T cell functions in blood collected from subjects treated with immunosuppressants in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384672     DOI: 10.1016/s0022-1759(01)00369-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  14 in total

1.  Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123.

Authors:  Ming-Sing Si; Bruce A Reitz; Dominic C Borie
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

Review 2.  A role for cytokine measurement in therapeutic monitoring of immunosuppressive drugs following lung transplantation.

Authors:  P A Corris; J A Kirby
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

3.  Effects of moderate and severe malnutrition in rats on splenic T lymphocyte subsets and activation assessed by flow cytometry.

Authors:  E Cortés-Barberena; H González-Márquez; J L Gómez-Olivares; R Ortiz-Muñiz
Journal:  Clin Exp Immunol       Date:  2008-03-28       Impact factor: 4.330

4.  Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors.

Authors:  Anjali Joshi; Himanshu Garg; Mary B Tompkins; Wayne A Tompkins
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Mycophenolic acid is a potent inhibitor of the expression of tumour necrosis factor- and tumour necrosis factor-receptor superfamily costimulatory molecules.

Authors:  Miranda M L Van Rijen; Herold J Metselaar; Martijn Hommes; Jan N M Ijzermans; Hugo W Tilanus; Jaap Kwekkeboom
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

6.  Immunomodulatory effects of docetaxel on human lymphocytes.

Authors:  Ming-Sing Si; David K Imagawa; Ping Ji; Xunbin Wei; Bari Holm; Jennifer Kwok; Michael Lee; Bruce A Reitz; Dominic C Borie
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

7.  Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation.

Authors:  Nassim Kamar; Petra Glander; Jochen Nolting; Torsten Böhler; Pia Hambach; Lutz Liefeldt; Lionel Rostaing; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-01       Impact factor: 8.237

8.  Immune response of healthy horses to DNA constructs formulated with a cationic lipid transfection reagent.

Authors:  Christiane L Schnabel; P Steinig; M Koy; H-J Schuberth; C Juhls; D Oswald; B Wittig; S Willenbrock; H Murua Escobar; C Pfarrer; B Wagner; P Jaehnig; A Moritz; K Feige; J-M V Cavalleri
Journal:  BMC Vet Res       Date:  2015-06-23       Impact factor: 2.741

9.  Flow cytometric evaluation of T cell activation markers after cardiopulmonary bypass.

Authors:  Maja-Theresa Dieterlen; Hartmuth B Bittner; Attila Tarnok; Jens Garbade; Stefan Dhein; Friedrich W Mohr; Markus J Barten
Journal:  Surg Res Pract       Date:  2014-02-06

10.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.